Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Immunocore Holdings plc ADR’s stock clocked out at $32.75, down -1.15% from its previous closing price of $33.13. In other words, the price has decreased by -$1.15 from its previous closing price. On the day, 0.54 million shares were traded. IMCR stock price reached its highest trading level at $33.51 during the session, while it also had its lowest trading level at $32.0.
Ratios:
To gain a deeper understanding of IMCR’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 577.93. For the most recent quarter (mrq), Quick Ratio is recorded 5.97 and its Current Ratio is at 6.00. In the meantime, Its Debt-to-Equity ratio is 1.10 whereas as Long-Term Debt/Eq ratio is at 1.09.
On October 31, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $60.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when Berman David M sold 31,341 shares for $40.26 per share. The transaction valued at 1,261,789 led to the insider holds 0 shares of the business.
Berman David M sold 572 shares of IMCR for $22,960 on Dec 05 ’25. The HEAD OF R&D now owns 0 shares after completing the transaction at $40.14 per share. On Nov 26 ’25, another insider, Berman David M, who serves as the HEAD OF R&D of the company, sold 69,404 shares for $40.12 each. As a result, the insider received 2,784,488 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMCR now has a Market Capitalization of 1654871296 and an Enterprise Value of 1198380160. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.35 while its Price-to-Book (P/B) ratio in mrq is 4.19. Its current Enterprise Value per Revenue stands at 3.157 whereas that against EBITDA is -51.071.
Stock Price History:
The Beta on a monthly basis for IMCR is 0.78, which has changed by 0.14162648 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, IMCR has reached a high of $40.71, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is -8.39%, while the 200-Day Moving Average is calculated to be -2.09%.
Shares Statistics:
It appears that IMCR traded 309.22K shares on average per day over the past three months and 386210 shares per day over the past ten days. A total of 50.47M shares are outstanding, with a floating share count of 50.08M. Insiders hold about 0.76% of the company’s shares, while institutions hold 97.65% stake in the company. Shares short for IMCR as of 1767139200 were 9520098 with a Short Ratio of 30.79, compared to 1764288000 on 8564719. Therefore, it implies a Short% of Shares Outstanding of 9520098 and a Short% of Float of 25.929999999999996.
Earnings Estimates
The stock of Immunocore Holdings plc ADR (IMCR) is currently in the spotlight, with 11.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.13, with high estimates of $0.02 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.11 and -$0.5 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.84, with 14.0 analysts recommending between $0.45 and -$2.28.
Revenue Estimates
In. The current quarter, 14 analysts expect revenue to total $108.22M. It ranges from a high estimate of $114.06M to a low estimate of $102.7M. As of. The current estimate, Immunocore Holdings plc ADR’s year-ago sales were $84.05MFor the next quarter, 14 analysts are estimating revenue of $108.5M. There is a high estimate of $115.8M for the next quarter, whereas the lowest estimate is $98.58M.
A total of 16 analysts have provided revenue estimates for IMCR’s current fiscal year. The highest revenue estimate was $409.6M, while the lowest revenue estimate was $398.3M, resulting in an average revenue estimate of $403.5M. In the same quarter a year ago, actual revenue was $310.2MBased on 16 analysts’ estimates, the company’s revenue will be $446.1M in the next fiscal year. The high estimate is $489M and the low estimate is $417.4M.
